Skip to main content
University of Michigan Innovation Partnerships
University of Michigan Innovation Partnerships

Portfolio

K-Space Associates, Inc.

Optical imaging using in-situ thin-film and wafer characterization technologies
(1992)

SoloHill Engineering, Inc.

Microcarriers and protocols for cell culture applications
(1992)

MC3

MC3 Cardiopulmonary, located in Dexter, was founded in 1991 by Robert Bartlett, M.D., a pioneering University of Michigan surgeon, and Scott Merz, PhD, to develop Extracorporeal Membrane Oxygenation (ECMO) technology for patients who would otherwise succumb to heart and lung disease.
(1991)

3D Static Strength Prediction Program

The 3D Static Strength Prediction Program™ (3D SSPP) is an effective way to analyze the biomechanics and safety of manual materials handling. The software allows the user to predict static strength requirements for common manual tasks like lifts, presses, pushes, and pulls.
(1990)

Aastrom

Developing autologous stem cell products for use in regenerative medicine
(1989)

BioQuant

Discovering and developing drugs for oncology, inflammation, immunology, & metabolic diseases
(1987)

TSRL, Inc.

Developing drug delivery solutions
(1987)

Arbor Ultrasound Technologies

Several ultrasound technologies for nephrologists

Cartox

In vitro cardiotoxicity testing platform using mature human stem cell derived cardiomyocytes

Endectra

Endectra LLC is commercializing solid-state, real-time radiation detection technology to displace expensive crystal- and gas-based sensors in defense, industrial, and medical applications.

ExoDynamics

Smart, active spinal orthoses that provides support and mobility to users

Health IT, LLC

Behavioral Healthcare company

Hipernap

Large stroke XY micro-stages

MEKanistic Therapeutics

MEKanistic is innovating cancer therapies by advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window while avoiding inherent toxicity challenges of multi-compound treatments. Preclinical studies of its lead drug MTX-531 show a high incidence of tumor regression with dramatically reduced toxicity.

STEL Technologies

Developing a bioengineered construct for ACL repair
1 17 18 19 20